1. Home
  2. REGN vs LYG Comparison

REGN vs LYG Comparison

Compare REGN & LYG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • REGN
  • LYG
  • Stock Information
  • Founded
  • REGN 1988
  • LYG 1695
  • Country
  • REGN United States
  • LYG United Kingdom
  • Employees
  • REGN N/A
  • LYG N/A
  • Industry
  • REGN Biotechnology: Pharmaceutical Preparations
  • LYG Commercial Banks
  • Sector
  • REGN Health Care
  • LYG Finance
  • Exchange
  • REGN Nasdaq
  • LYG Nasdaq
  • Market Cap
  • REGN 56.7B
  • LYG 61.3B
  • IPO Year
  • REGN 1991
  • LYG N/A
  • Fundamental
  • Price
  • REGN $567.74
  • LYG $4.11
  • Analyst Decision
  • REGN Buy
  • LYG Hold
  • Analyst Count
  • REGN 22
  • LYG 3
  • Target Price
  • REGN $840.95
  • LYG N/A
  • AVG Volume (30 Days)
  • REGN 987.0K
  • LYG 12.7M
  • Earning Date
  • REGN 08-01-2025
  • LYG 07-24-2025
  • Dividend Yield
  • REGN 0.62%
  • LYG 4.00%
  • EPS Growth
  • REGN 16.49
  • LYG N/A
  • EPS
  • REGN 39.43
  • LYG 0.08
  • Revenue
  • REGN $14,085,700,000.00
  • LYG $22,686,339,623.00
  • Revenue This Year
  • REGN N/A
  • LYG $9.48
  • Revenue Next Year
  • REGN $6.77
  • LYG $8.15
  • P/E Ratio
  • REGN $14.40
  • LYG $12.17
  • Revenue Growth
  • REGN 7.52
  • LYG N/A
  • 52 Week Low
  • REGN $476.49
  • LYG $2.56
  • 52 Week High
  • REGN $1,211.20
  • LYG $4.30
  • Technical
  • Relative Strength Index (RSI)
  • REGN 63.13
  • LYG 47.20
  • Support Level
  • REGN $532.60
  • LYG $4.09
  • Resistance Level
  • REGN $559.46
  • LYG $4.19
  • Average True Range (ATR)
  • REGN 14.29
  • LYG 0.05
  • MACD
  • REGN 6.52
  • LYG -0.01
  • Stochastic Oscillator
  • REGN 98.82
  • LYG 43.10

About REGN Regeneron Pharmaceuticals Inc.

Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including low-dose Eylea and Eylea HD, approved for wet age-related macular degeneration and other eye diseases; Dupixent in immunology; Praluent for LDL cholesterol lowering; Libtayo in oncology; and Kevzara in rheumatoid arthritis. Regeneron is also developing monoclonal and bispecific antibodies with Sanofi, other collaborators, and independently, and has earlier-stage partnerships that bring new technology to the pipeline, including RNAi (Alnylam) and Crispr-based gene editing (Intellia).

About LYG Lloyds Banking Group Plc

Lloyds is a retail and commercial bank headquartered in the United Kingdom. The bank operates via three business segments: retail, commercial banking, and insurance and wealth. In retail, Lloyds offers primarily mortgages (66% of loan portfolio), credit cards, and current accounts to its customers. Its commercial banking operation provides lending, transaction banking, working capital management, and debt capital market services to large companies and financial institutions in the UK Insurance and wealth rounds out the product lineup with life and property insurance as well as pension solutions and high-net-worth asset-management services.

Share on Social Networks: